Logo image of MTEM

MOLECULAR TEMPLATES INC (MTEM) Stock News

NASDAQ:MTEM - Nasdaq - US6085502085 - Common Stock

0.1072  -0.03 (-23.43%)

After market: 0.1113 +0 (+3.82%)

MTEM Latest News and Analysis

News Image
a month ago - Benzinga

Why Molecular Templates (MTEM) Stock Is Down 60%

Molecular Templates shares are trading lower by 54% during Friday's session. The company announced it received a Nasdaq delisting notice.

News Image
a month ago - Molecular Templates, Inc.

Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules

AUSTIN, Texas, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a...

News Image
2 months ago - Molecular Templates, Inc.

Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements

AUSTIN, Texas, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a...

News Image
5 months ago - InvestorPlace

MTEM Stock Earnings: Molecular Templates Beats EPS, Beats Revenue for Q2 2024

MTEM stock results show that Molecular Templates beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

News Image
5 months ago - BusinessInsider

MTEM Stock Earnings: Molecular Templates Beats EPS, Beats Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Molecular Templates (NASDAQ:MTEM) just reported results for the second quarter ...

News Image
5 months ago - Molecular Templates, Inc.

Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update

Monotherapy activity of long duration in patients who have progressed on checkpoint therapy via a novel immuno-oncology mechanism of action with PD-L1 ETB...

News Image
7 months ago - InvestorPlace

7 F-Rated Penny Stocks to Avoid This June

These F-rated penny stocks have the lowest ratings from the Portfolio Grader based on factors like earnings, growth and momentum.

News Image
8 months ago - Molecular Templates, Inc.

Molecular Templates, Inc. Provides Interim Update

Continued monotherapy activity in solid tumors with MT-6402 (PD-L1-targeting ETB) in checkpoint-experienced patients.Early pre-clinical and clinical data...

News Image
8 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to dive into the biggest pre-market stock movers for Thursday as we check out all of the hottest news this morning!

News Image
8 months ago - InvestorPlace

MTEM Stock Earnings: Molecular Templates Beats EPS, Beats Revenue for Q1 2024

MTEM stock results show that Molecular Templates beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

News Image
8 months ago - BusinessInsider

MTEM Stock Earnings: Molecular Templates Beats EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Molecular Templates (NASDAQ:MTEM) just reported results for the first quarter o...

News Image
8 months ago - Molecular Templates, Inc.

Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update

AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...

News Image
10 months ago - InvestorPlace

MTEM Stock Earnings: Molecular Templates Beats EPS, Misses Revenue for Q4 2023

MTEM stock results show that Molecular Templates beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.

News Image
10 months ago - BusinessInsider

MTEM Stock Earnings: Molecular Templates Beats EPS, Misses Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Molecular Templates (NASDAQ:MTEM) just reported results for the fourth quarter ...

News Image
10 months ago - Molecular Templates, Inc.

Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer

AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...